Panelists. ABA 31 st Annual National Institute on White Collar Crime. Healthcare Fraud and Abuse Panel

Size: px
Start display at page:

Download "Panelists. ABA 31 st Annual National Institute on White Collar Crime. Healthcare Fraud and Abuse Panel"

Transcription

1 Prepared for ABA 31 st Annual National Institute on White Collar Crime Healthcare Fraud and Abuse Panel March 8, 2017 Panelists Greg Noonan (Moderator) Collora LLP Boston, Massachusetts Joseph F. Savage Goodwin LLP Boston, Massachusetts Laura G. Hoey Ropes & Gray LLP Chicago, Illinois Paul J. Fishman United States Attorney District of New Jersey Newark, New Jersey Catherine Dick Trial Attorney Organized Crime and Gang Section U.S. Department of Justice Washington, DC

2 2016 Statistics Health Care Fraud and Abuse Control Program Annual Report for Fiscal Year 2016: Over $3.3 billion recovered in civil and criminal healthcare fraud matters Criminal Actions in FY 2016: DOJ instituted 975 new criminal healthcare fraud investigations Criminal charges were filed in 480 cases involving 802 defendants 658 defendants were convicted of healthcare fraud-related crimes Civil Actions in FY 2016: DOJ instituted 930 new civil healthcare fraud investigations 1,422 civil matters were pending at the end of FY 2016 HHS-OIG excluded 3,635 individuals and entities from participation in federal healthcare programs Trends in Corporate Prosecutions Substantial focus in 2016 on corporate accountability and cooperation: Factors prosecutors should consider in investigating corporate entities, determining whether to bring charges, and negotiating plea agreements? New guidance on Evaluation of Corporate Compliance Programs issued by DOJ Criminal Division - Fraud Section on February 8, 2017 DOJ process for assessing corporate cooperation?

3 Trends in Corporate Prosecutions Notable corporate resolutions in 2016: Olympus Corp. (March 2016): distributor of endoscopes and related equipment paid $623.2 million ($312.4 million criminal penalty and $310.8 million civil FCA payment) to resolve criminal charges and civil FCA claims relating to a scheme to pay kickbacks to doctors and hospitals Largest total amount paid for AKS violations by a medical device manufacturer Resolution included a three-year Deferred Prosecution Agreement with DOJ and a five-year Corporate Integrity Agreement with HHS-OIG McKesson Corp. (Jan. 2017): McKesson agreed to pay a $150 million civil penalty for failure to implement and adhere to an effective system to detect and report suspicious orders for controlled substances The company was required to implement a compliance program as a result of similar violations in 2008 The new settlement imposes enhanced terms for five additional years and requires McKesson to engage an independent monitor to assess compliance Trends in Corporate Prosecutions Heightened interest in cases involving patient harm, threat of harm, and medically unnecessary services: United States v. Cadden et al. (NECC): former owner and head pharmacist of New England Compounding Pharmacy and other affiliated individuals charged with RICO conspiracy, mail and wire fraud, and FDCA violations in connection with patient deaths caused by a fungal meningitis outbreak allegedly resulting from defendants knowing failure to ensure drugs manufactured in sanitary environment First trial began in January 2017; two trials to follow United States v. Babich (Insys): several former executives of Insys Therapeutics indicted in December 2016 for RICO conspiracy, conspiracy to violate the AKS, and other charges, based on an alleged conspiracy to bribe practitioners to unnecessarily prescribe an addictive Fentanyl-based pain medication Tenet Healthcare: in October 2016 Tenet Healthcare agreed to pay a total of $513 million to resolve criminal charges and civil claims for allegedly bribing a pre-natal clinic to refer over 20,000 Medicaid patients to Tenet hospitals

4 AKS Violations as Predicate for FCA Liability Significant resolutions in addition to Olympus Corp. and Tenet Healthcare: Novartis (Nov. 2015): Novartis agreed to pay $390 million to resolve allegations under the FCA that it gave kickbacks to specialty pharmacies to recommend its products Shire Pharmaceuticals (January 2017): Shire and several of its subsidiaries agreed to pay $350 million to resolve civil state and federal FCA and AKS claims arising from a set of six qui tam lawsuits Cases still require proof of every element of the criminal AKS statute. Where does DOJ go from here? Will the new administration take a different approach to corporate prosecutions?

5 Trends in Individual Prosecutions In the wake of the Yates Memo, DOJ focused on holding individual executives responsible for corporate wrongdoing Notable Individual Prosecutions in 2016: United States v. Vascular Solutions and Howard Root (W.D. Tex.) United States v. Carl Reichel (D. Mass.) United States v. William Facteau and Patrick Fabian (D. Mass.) U.S. v. Vascular Solutions and Root (W.D. Tex.) July 2014: Vascular Solutions agreed to pay $520,000 to resolve qui tam suit alleging that company marketed the Vari-Lase Short Kit (a varicose vein treatment) for off-label uses Nov. 2014: Federal grand jury in San Antonio indicted Company and CEO Howard Root Government alleged that Root coached the sales force to promote the Vari-Lase Short Kit to treat veins deep in the leg, when it was FDAcleared only to treat superficial veins Defendants argued that this treatment was on-label, and that the alleged conduct concerned truthful and non-misleading speech protected by the First Amendment The court instructed the jury that solely truthful and not misleading speech to doctors could not be the basis for a misbranding conviction Feb. 2016: Company and CEO were acquitted of all charges

6 U.S. v. Carl Reichel (D. Mass.) Oct. 2015: former Warner Chilcott President, Carl Reichel, was arrested for one count of conspiracy to violate the AKS The same day, Warner Chilcott agreed to plead guilty to a felony health care fraud charge and to pay $125 million to resolve civil and criminal liability based on alleged AKS violations Reichel s indictment came after four-year investigation: 300+ witnesses interviewed, 50+ of which testified before the grand jury Government initially alleged that Reichel led a company-wide scheme to bribe doctors with free dinners and speaker fees Despite extensive investigation, little evidence of wrongdoing could be tied to Reichel and, as trial neared, government s theory collapsed from company-wide to involving only a dozen or so individuals Government cut witness list in half and did not call any of Reichel s direct reports at trial June 2016: following a month-long trial, the jury acquitted Reichel after deliberating less than three hours U.S. v. Facteau and Fabian (D. Mass.) July 2016: Acclarent, Inc. agreed to pay $18 million to resolve civil FCA liability for marketing and distributing Relieva Stratus sinus spacer for unapproved uses April 2015: Federal grand jury in Boston indicted former Acclarent Inc. CEO William Facteau and VP of Sales Patrick Fabian on FDCA off-label promotion charges Government alleged that defendants directed sales force to promote the Stratus device for an unapproved use as a drug delivery mechanism Defendants argued that they made only non-misleading, truthful statements about Stratus s off-label use Feb. 2016: following a six-week trial, Defendants were acquitted of ten felony misbranding charges, but convicted of ten misdemeanor counts under Park Defendants have challenged their convictions for strict liability misdemeanors on due process grounds Motion for Judgment of Acquittal is pending in D. Mass.

7 Themes in Individual Prosecutions Disconnect between Government and jurors in how they view severity of crime Jurors reluctant to find executives guilty based just on position Jurors may think that executives commit crimes but not that this executive committed a crime Violation of company rules violation of law Selling crime Just because corporation is found guilty does not mean executive will be Government view is that statutes are clear, but jurors may not think so Where does DOJ go from here? Is the focus on individual responsibility likely to change under the new administration?

8 Areas to Watch in 2017 Will DOJ seek to use RICO more broadly in the healthcare context? When should RICO be used? Experience with RICO in healthcare cases Current healthcare-related RICO prosecutions: Insys: former executives face RICO charges for allegedly bribing doctors to prescribe Fentanyl-based medication (Subsys) for off-label use in non-cancer patients and conspiring to defraud insurers by setting up reimbursement unit to obtain PAs for off-label uses Indictment alleges that Insys constitutes a racketeering enterprise NECC: former owner and head pharmacist indicted on RICO charges for roles in deadly fungal meningitis outbreak caused by contaminated vials of NECC-manufactured drug Charged with 25 predicate acts of second-degree murder Areas to Watch in 2017 The new wave of Anti-Kickback prosecutions: Increased Scrutiny of Drug Pricing and Patient Assistance Programs Prosecutions of Providers who receive kickbacks Use of Travel Act Use of Commercial Bribery

9 Qui Tam Actions How often does the government intervene in qui tam actions? What factors does the government consider in deciding whether to intervene? In what types of cases has the government been most likely to intervene? Qui Tam Actions Effect of Qui Tam lawsuit on parallel criminal investigation? How might actions taken in the civil proceeding affect resolution of the criminal matter? Considerations for the government? Strategies for defense counsel? When are global resolutions of civil and criminal proceedings available? Strategies for defense counsel when DOJ not willing to entertain a global resolution?

Will Life Sciences Companies Face More Scrutiny In 2018?

Will Life Sciences Companies Face More Scrutiny In 2018? Will Life Sciences Companies Face More Scrutiny In 2018? By John Bentivoglio and Jennifer Bragg The pace of U.S. Department of Justice settlements with life sciences companies slowed in 2017, with eight

More information

From the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits

From the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits From the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits BUTLER SNOW 1 UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT

More information

SESSION OVERVIEW The Yates Memo and its Legal Implications in Corporate Investigations.

SESSION OVERVIEW The Yates Memo and its Legal Implications in Corporate Investigations. COMPLIANCE CHALLENGES IN THE YATES MEMO ERA HCCA S 21 ST ANNUAL COMPLIANCE INSTITUTE, March 27, 2017 Gina Simms, Esq. George Breen, Esq. Tarra DeShields, AUSA District of Maryland SESSION OVERVIEW The

More information

How Pharma Cos. Can Lessen The Risk Of Gov't Action

How Pharma Cos. Can Lessen The Risk Of Gov't Action Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com How Pharma Cos. Can Lessen The Risk Of Gov't Action

More information

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs United States Government Accountability Office Report to Congressional Requesters April 2018 DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of Inspector General s Use of Agreements to Protect the Integrity

More information

FAST BREAK: GOVERNMENT ENFORCEMENT OF INDIVIDUAL ACCOUNTABILITY. Katie McDermott Jacob Harper February 28, Morgan, Lewis & Bockius LLP

FAST BREAK: GOVERNMENT ENFORCEMENT OF INDIVIDUAL ACCOUNTABILITY. Katie McDermott Jacob Harper February 28, Morgan, Lewis & Bockius LLP FAST BREAK: 2015 Morgan, Lewis & Bockius LLP GOVERNMENT ENFORCEMENT OF INDIVIDUAL ACCOUNTABILITY Katie McDermott Jacob Harper February 28, 2017 2015 Morgan, Lewis & Bockius LLP Discussion Agenda Individual

More information

PATRICK S. COFFEY. Chicago, IL office: office:

PATRICK S. COFFEY. Chicago, IL office: office: PATRICK S. COFFEY Partner Milwaukee, WI Chicago, IL office: 312.523.2080 office: 414.978.5538 email: patrick.coffey@ Overview When clients are faced with difficult problems, Pat puts them at ease. He uses

More information

Telemedicine Fraud and Abuse Under the Microscope

Telemedicine Fraud and Abuse Under the Microscope Telemedicine Fraud and Abuse Under the Microscope Session 232, February 14, 2019 Douglas Grimm, Esq., Arent Fox LLP Hillary Stemple, Esq., Arent Fox LLP 1 Conflicts of Interest Douglas Grimm, Esq. Has

More information

False Claims Act Enforcement in the Managed Care Space: Recent Trends and Proactive Compliance Tips

False Claims Act Enforcement in the Managed Care Space: Recent Trends and Proactive Compliance Tips False Claims Act Enforcement in the Managed Care Space: Recent Trends and Proactive Compliance Tips Thomas Clarkson* U.S. Attorney s Office Southern District of Georgia Scott R. Grubman Chilivis Cochran

More information

U.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned

U.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned U.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned Presented By: David O Brien Christine Rinn Michael Paddock HOOPS 2007 - Washington, DC October 15-16 Background June 1994:

More information

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com

More information

The False Claims Act and Off-Label Promotion: Understanding and Minimizing the Risks for Pharmaceutical Manufacturers

The False Claims Act and Off-Label Promotion: Understanding and Minimizing the Risks for Pharmaceutical Manufacturers 4th Annual Pharmaceutical Regulatory Congress November 12, 2003 The False Claims Act and Off-Label Promotion: Understanding and Minimizing the Risks for Pharmaceutical Manufacturers John T. Bentivoglio

More information

11/10/2014. Nuts and Bolts of Proceedings related to Fraud, Recent Cases Update, and HIPAA Nuances. Objectives

11/10/2014. Nuts and Bolts of Proceedings related to Fraud, Recent Cases Update, and HIPAA Nuances. Objectives Nuts and Bolts of Proceedings related to Fraud, Recent Cases Update, and HIPAA Nuances Presented to: Health Care Compliance Association November 14, 2014 Objectives Background and General Trends on fraud

More information

NewYork-Presbyterian Hospital Sites: All Centers Hospital Policy and Procedure Manual Number: D160 Page 1 of 8

NewYork-Presbyterian Hospital Sites: All Centers Hospital Policy and Procedure Manual Number: D160 Page 1 of 8 Page 1 of 8 TITLE: FEDERAL DEFICIT REDUCTION ACT OF 2005 FRAUD AND ABUSE PROVISIONS POLICY: NewYork- Presbyterian Hospital (NYP or the Hospital) is committed to preventing and detecting any fraud, waste,

More information

This course is designed to provide Part B providers with an overview of the Medicare Fraud and Abuse program including:

This course is designed to provide Part B providers with an overview of the Medicare Fraud and Abuse program including: This course is designed to provide Part B providers with an overview of the Medicare Fraud and Abuse program including: Medicare Trust Fund Defining Fraud & Abuse Examples of Fraud & Abuse Fraud & Abuse

More information

SUNY DOWNSTATE MEDICAL CENTER POLICY AND PROCEDURE. No:

SUNY DOWNSTATE MEDICAL CENTER POLICY AND PROCEDURE. No: SUNY DOWNSTATE MEDICAL CENTER POLICY AND PROCEDURE Subject: Complying with the Deficit Reduction Act of 2005: Detection & Prevention of Fraud, Waste & Abuse Page 1 of 4 Prepared by: Shoshana Milstein Original

More information

GERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036

GERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski

More information

David J. Leviss Partner

David J. Leviss Partner David J. Leviss Partner Washington, DC D: +1-202-383-5282 dleviss@omm.com A recognized authority on False Claims Act-related issues, David Leviss focuses his practice on defending corporations and individuals

More information

EMERGING TRENDS IN LATIN AMERICA

EMERGING TRENDS IN LATIN AMERICA EMERGING TRENDS IN LATIN AMERICA 17 th Annual Pharmaceutical & Medical Device Compliance Congress Colleen Conry Michael Casey Partner, Ropes & Gray LLP Counsel, Ropes & Gray LLP 1 1 October 13, 2016 AGENDA

More information

Conflicts of Interest 9/10/2017. Everything a Health Care Executive Needs to Know about the Anti-Kickback Statute. May 2, 2017 Article from JAMA:

Conflicts of Interest 9/10/2017. Everything a Health Care Executive Needs to Know about the Anti-Kickback Statute. May 2, 2017 Article from JAMA: Everything a Health Care Executive Needs to Know about the Anti-Kickback Statute Matthew Krueger Assistant United States Attorney E.D. of Wisconsin Stacy Gerber Ward von Briesen & Roper, S.C. Conflicts

More information

1/29/2011. Mark G. Bodner Bureau Chief Complex Civil Enforcement Bureau Medicaid Control Unit Office of the Attorney General

1/29/2011. Mark G. Bodner Bureau Chief Complex Civil Enforcement Bureau Medicaid Control Unit Office of the Attorney General Mark G. Bodner Bureau Chief Complex Civil Enforcement Bureau Medicaid Control Unit Office of the Attorney General The enactment of the Medicare and Medicaid Anti-Fraud and Abuse Amendments of 1977 authorized

More information

MATTHEW T. SCHELP. St. Louis, MO office:

MATTHEW T. SCHELP. St. Louis, MO office: MATTHEW T. SCHELP Partner St. Louis, MO office: 314.480.1772 email: matthew.schelp@ Overview A former federal prosecutor, Matt concentrates his practice in the areas of compliance, internal investigations,

More information

Current Issues in Patient and Product Support. October 20, 2016

Current Issues in Patient and Product Support. October 20, 2016 Current Issues in Patient and Product Support October 20, 2016 How Did a Perennial Issue Become the Hot Topic? 1. Reimbursement Support 2. Patient Assistance Programs 3. Donations to Charitable Foundations

More information

FRAUD, WASTE, & ABUSE (FWA) for Brokers. revised 10/17

FRAUD, WASTE, & ABUSE (FWA) for Brokers. revised 10/17 FRAUD, WASTE, & ABUSE (FWA) for Brokers revised 10/17 OBJECTIVES After reviewing this information, you will be able to: Understand Fraud, Waste, and Abuse (FWA) training requirements; Be familiar with

More information

FCPA. Due Diligence. The REPORT. The Importance of Pre-Merger Due Diligence

FCPA. Due Diligence. The REPORT. The Importance of Pre-Merger Due Diligence Due Diligence Critical Steps to Take and Questions to Ask When Conducting Pre-Merger Anti-Corruption Due Diligence By Michael J. Gilbert and Mauricio A. España, Dechert LLP There is no doubt that the most

More information

This webinar is sponsored by the Fraud and Abuse Practice Group.

This webinar is sponsored by the Fraud and Abuse Practice Group. Trends in Health Care Enforcement: Past, Present, and Future July 21, 2014 3:30-4:45 Eastern This webinar is sponsored by the Fraud and Abuse Practice Group. Faculty : Susan Winkler Assistant U.S. Attorney,

More information

Fraud and Abuse Compliance for the Health IT Industry

Fraud and Abuse Compliance for the Health IT Industry Fraud and Abuse Compliance for the Health IT Industry Session 89, March 6, 2018 James A. Cannatti III, Senior Counselor for Health Information Technology, U.S. Department of Health and Human Services (HHS),

More information

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable state

More information

Fraud in the Pharmaceutical Industry

Fraud in the Pharmaceutical Industry Fraud in the Pharmaceutical Industry The United States qui tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax:

More information

The False Claims Act. False Claims Act Basics (I)

The False Claims Act. False Claims Act Basics (I) The False Claims Act Basic Concepts, Recent Trends, and Strategies for Minimizing Risks Philip D. Robben February 26, 2013 False Claims Act Basics (I)! Imposes liability on those who submit false claims

More information

R E P R I N T JAN-MAR Inside this issue: The evolving role of the chief risk officer Managing your company s regulatory exposure

R E P R I N T JAN-MAR Inside this issue: The evolving role of the chief risk officer Managing your company s regulatory exposure R E P R I N T RC & risk compliance & NEW DOJ POLICIES MAY HELP COMPANIES BETTER NAVIGATE FALSE CLAIMS ACT INVESTIGATIONS REPRINTED FROM: RISK & COMPLIANCE MAGAZINE OCT-DEC 2018 ISSUE RC & risk & compliance

More information

Cardinal McCloskey Community Services. Corporate Compliance. False Claims Act and Whistleblower Provisions

Cardinal McCloskey Community Services. Corporate Compliance. False Claims Act and Whistleblower Provisions Cardinal McCloskey Community Services Corporate Compliance False Claims Act and Whistleblower Provisions Purpose: Cardinal McCloskey Community Services is committed to prompt, complete and accurate billing

More information

Anti-Kickback Statute and False Claims Act Enforcement

Anti-Kickback Statute and False Claims Act Enforcement Anti-Kickback Statute and False Claims Act Enforcement Nicholas Gachassin, III, Esq. Gachassin Law Firm, LLC Nick3@gachassin.com Press Conference on Health Care Fraud and the Affordable Care Act May 13,

More information

Defending Whistleblower Cases: An Advanced View From the Trenches. Gregory M. Luce Jones Day

Defending Whistleblower Cases: An Advanced View From the Trenches. Gregory M. Luce Jones Day Defending Whistleblower Cases: An Advanced View From the Trenches Gregory M. Luce Jones Day www.hcca-info.org 888-580-8373 Whistleblower Actions False Claims Act Statute prohibiting fraud against the government

More information

False Claims Act and Mandatory Disclosure Requirements for Federal Contractors

False Claims Act and Mandatory Disclosure Requirements for Federal Contractors False Claims Act and Mandatory Disclosure Requirements for Federal Contractors Presenters: Robert T. Rhoad, Esq. & Dalal Hasan, Esq. 2012 Crowell & Moring LLP All Rights Reserved False Claims Act: Recent

More information

False Claims Act and Mandatory Disclosure Requirements for Federal Contractors

False Claims Act and Mandatory Disclosure Requirements for Federal Contractors False Claims Act and Mandatory Disclosure Requirements for Federal Contractors Presenters: Robert T. Rhoad, Esq. & Dalal Hasan, Esq. 2012 Crowell & Moring LLP All Rights Reserved False Claims Act: Recent

More information

Managing Financial Interests: The Anti Kickback Statute (AKS)

Managing Financial Interests: The Anti Kickback Statute (AKS) Managing Financial Interests: The Anti Kickback Statute (AKS) Board of Commissioners Meeting February 15, 2012 Presented by: Mic Sager, Compliance Officer Context: Business Transactions o Health Care is

More information

Effective Date: 1/01/07 N/A

Effective Date: 1/01/07 N/A North Shore-LIJ Health System is now Northwell Health POLICY TITLE: Detecting and Preventing Fraud, Waste, Abuse and Misconduct POLICY #: 800.09 System Approval Date: 03/30/2017 Site Implementation Date:

More information

REGULATORY ISSUES IMPACTING SUPPLY CHAIN

REGULATORY ISSUES IMPACTING SUPPLY CHAIN REGULATORY ISSUES IMPACTING SUPPLY CHAIN Michael Nachman Associate General Counsel John W. Jones, Jr. Partner Allan A. Thoen Partner April 27, 2017 2017 In House Counsel Conference Presenters: John W.

More information

Potential Perils of Using New Media in Marketing and Promotion. Christina M. Markus (202)

Potential Perils of Using New Media in Marketing and Promotion. Christina M. Markus (202) Potential Perils of Using New Media in Marketing and Promotion Christina M. Markus (202) 626-2926 cmarkus@kslaw.com FACEBOOK Using Facebook to develop online community TWITTER Using Twitter as another

More information

SOUTH NASSAU COMMUNITIES HOSPITAL One Healthy Way, Oceanside, NY 11572

SOUTH NASSAU COMMUNITIES HOSPITAL One Healthy Way, Oceanside, NY 11572 SOUTH NASSAU COMMUNITIES HOSPITAL One Healthy Way, Oceanside, NY 11572 POLICY TITLE: Compliance with Applicable Federal and State False Claims Acts POLICY NUMBER: OF-ADM-232 DEPARTMENT: Hospital-wide BACKGROUND/PURPOSE

More information

Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures

Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures Prepared for CBI s Pharmaceutical Compliance Congress April 28, 2017 M&A Activity in the Pharmaceutical Industry THE

More information

Certifying Employee Training Navicent Health s Corporate Integrity Agreement Year Two

Certifying Employee Training Navicent Health s Corporate Integrity Agreement Year Two Certifying Employee Training Navicent Health s Corporate Integrity Agreement Year Two Corporate Integrity Agreement Effective 4/23/2015 Term of five years Basic Requirement: Maintain a Compliance Program

More information

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective International In-house Counsel Journal Vol. 4, No. 13, Autumn 2010, 1 The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective LESLIE

More information

Insert Slide Title. Jennifer A. Romanski, Esq. February 8, 2017

Insert Slide Title. Jennifer A. Romanski, Esq. February 8, 2017 Insert Slide Title Jennifer A. Romanski, Esq. February 8, 2017 Interactions/Engagements with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) Consulting Payments Service Arrangements

More information

The Perils Of Pharma: The Pharmaceutical Industry And The FCPA

The Perils Of Pharma: The Pharmaceutical Industry And The FCPA W O R L D - C H E C K W H I T E P A P E R The Perils Of Pharma: The Pharmaceutical Industry And The FCPA by Michael Osajda Statement of intent In recent years, the pharmaceutical industry has been subjected

More information

Corporate Integrity Agreements can be the basis for a False Claims Act Case

Corporate Integrity Agreements can be the basis for a False Claims Act Case Corporate Integrity Agreements can be the basis for a False Claims Act Case by Suzanne E. Durrell, Esq. Washington D.C. November 2014 Who should read this paper Presented by Atty. Suzanne E. Durrell at

More information

The Intersection of Specialty Pharmacy and the Law

The Intersection of Specialty Pharmacy and the Law The Intersection of Specialty Pharmacy and the Law Target Audience: Pharmacists ACPE#: 0202-0000-18-018-L03-P Activity Type: Knowledge-based Disclosures I declare that neither I nor any immediate family

More information

Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII

Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII The 16 th Pharmaceutical Compliance Congress and Best Practices Forum Thursday, October

More information

Corporate Compliance Topic: False Claims Act and Whistleblower Provisions

Corporate Compliance Topic: False Claims Act and Whistleblower Provisions Purpose: INDEPENDENT LIVING, Inc. (also referred to as ILI, ) is committed to prompt, complete and accurate billing of all services provided to individuals. ILI and its employees, contractors and agents

More information

What s On Tap? Who Are the Players? 4/3/2017. Healthcare Enforcement Trends What To Do When the Government Comes Knocking?

What s On Tap? Who Are the Players? 4/3/2017. Healthcare Enforcement Trends What To Do When the Government Comes Knocking? Healthcare Enforcement Trends What To Do When the Government Comes Knocking? Holly Logan Craig Sieverding 1 What s On Tap? Enforcement landscape, generally Fraud and Abuse Update o Brief primer on major

More information

Office of Inspector General. Regional Enforcement Efforts and Priorities in Florida. South Atlantic Regional Conference January 28, 2011

Office of Inspector General. Regional Enforcement Efforts and Priorities in Florida. South Atlantic Regional Conference January 28, 2011 Office of Inspector General Regional Enforcement Efforts and Priorities in Florida Health Care Compliance Association South Atlantic Regional Conference January 28, 2011 Felicia Heimer, Esq. Office of

More information

New Government Theories of Civil Liability for Off-Label Promotion: Are They Legitimate?

New Government Theories of Civil Liability for Off-Label Promotion: Are They Legitimate? BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE TOKYO WASHINGTON, D.C. New Government Theories of Civil Liability for Off-Label Promotion:

More information

Effective Date: 5/31/2007 Reissue Date: 10/08/2018. I. Summary of Policy

Effective Date: 5/31/2007 Reissue Date: 10/08/2018. I. Summary of Policy Issuing Department: Internal Audit, Compliance, and Enterprise Risk Management Preventing Fraud, Waste, and Abuse: Federal and State False Claims and False Statements Effective Date: 5/31/2007 Reissue

More information

Federal Fraud and Abuse Enforcement in the ASC Space

Federal Fraud and Abuse Enforcement in the ASC Space Federal Fraud and Abuse Enforcement in the ASC Space SCOTT R. GRUBMAN, ESQ. PARTNER CHILIVIS COCHRAN LARKINS & BEVER, LLP (ATLANTA GA) Fraud & Abuse Enforcement Landscape FBI CMS OCR MFCU DCIS DOJ HHS-OIG

More information

OKALOOSA SHERIFF PRAISES WORK OF NEW MORTGAGE FRAUD TASK FORCE

OKALOOSA SHERIFF PRAISES WORK OF NEW MORTGAGE FRAUD TASK FORCE September 30, 2011 OKALOOSA SHERIFF PRAISES WORK OF NEW MORTGAGE FRAUD TASK FORCE Okaloosa County Sheriff Larry Ashley today praised the work of the newly formed Northwest Florida Mortgage Fraud Task Force,

More information

AGENCY POLICY. IDENTIFICATION NUMBER: CCD001 DATE APPROVED: Nov 1, 2017 POLICY NAME: False Claims & Whistleblower SUPERSEDES: May 18, 2009

AGENCY POLICY. IDENTIFICATION NUMBER: CCD001 DATE APPROVED: Nov 1, 2017 POLICY NAME: False Claims & Whistleblower SUPERSEDES: May 18, 2009 IDENTIFICATION NUMBER: CCD001 DATE APPROVED: Nov 1, 2017 POLICY NAME: False Claims & Whistleblower SUPERSEDES: May 18, 2009 Provisions OWNER S DEPARTMENT: Compliance APPLICABILITY: All Agency Programs

More information

7/25/2018. Government Enforcement in the Clinical Laboratory Space. The Statutes & Regulations. The Stark Law. The Stark Law.

7/25/2018. Government Enforcement in the Clinical Laboratory Space. The Statutes & Regulations. The Stark Law. The Stark Law. Government Enforcement in the Clinical Laboratory Space 2 SCOTT R. GRUBMAN, ESQ. The Statutes & Regulations 3 4 AKA the physician self-referral law The Rule: If physician (or immediate family member) has

More information

DOJ OPINION LIMITING THE SCOPE OF CRIMINAL ENFORCEMENT UNDER HIPAA ISSUED JUNE 1, Houston (832) (800)

DOJ OPINION LIMITING THE SCOPE OF CRIMINAL ENFORCEMENT UNDER HIPAA ISSUED JUNE 1, Houston (832) (800) DOJ OPINION LIMITING THE SCOPE OF CRIMINAL ENFORCEMENT UNDER HIPAA ISSUED JUNE 1, 2005 By: Katherine M. Layman, Esquire, Brad M. Rostolsky, Esquire 1900 Market Street Philadelphia PA, 19103 215.665.2000

More information

This policy applies to all employees, including management, contractors, and agents. For purpose of this policy, a contractor or agent is defined as:

This policy applies to all employees, including management, contractors, and agents. For purpose of this policy, a contractor or agent is defined as: Policy and Procedure: Corporate Compliance Topic: Purpose: Choice of NY is committed to prompt, complete, and accurate billing of all services provided to individuals. Choice of NY and its employees, contractors,

More information

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016 Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington

More information

LITIGATING AWP. Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002

LITIGATING AWP. Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002 LITIGATING AWP Mitch Lazris/Lyndon Tretter Hogan & Hartson L.L.P. November 15, 2002 Litigation Landscape Federal Gov t/states/private Class Actions Payment Systems Medicare (based on 95% of AWP) Medicare

More information

STATE OF OHIO LAVELLE COLEMAN

STATE OF OHIO LAVELLE COLEMAN [Cite as State v. Coleman, 2008-Ohio-2806.] Court of Appeals of Ohio EIGHTH APPELLATE DISTRICT COUNTY OF CUYAHOGA JOURNAL ENTRY AND OPINION No. 89358 STATE OF OHIO PLAINTIFF-APPELLEE vs. LAVELLE COLEMAN

More information

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS

DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable

More information

Whistleblowing Under the False Claims Act

Whistleblowing Under the False Claims Act Whistleblowing Under the False Claims Act Session 303, March 9, 2018 Colette G. Matzzie, Partner, Phillips & Cohen LLP Brendan Delaney, Implementation Specialist, Whistleblower 1 Conflict of Interest Colette

More information

The False Claims Act (FCA): Where We Are, And What s Ahead

The False Claims Act (FCA): Where We Are, And What s Ahead The False Claims Act (FCA): Where We Are, And What s Ahead Tuesday, March 14, 2017 @ 12:00 pm ET Host: Mark Burroughs Guest: Peter Hutt II, Covington & Burling LLP Preface Welcome to Deloitte s Trending

More information

American Academy of Orthopaedic Surgeons 2010 Annual Meeting. March 12, 2010

American Academy of Orthopaedic Surgeons 2010 Annual Meeting. March 12, 2010 American Academy of Orthopaedic Surgeons 2010 Annual Meeting March 12, 2010 Developments in the Evolving Orthopaedic Surgeon - Industry Relationship Kathleen McDermott, Esquire Washington, DC 1 Developments

More information

Region 10 PIHP FY Corporate Compliance Program Plan

Region 10 PIHP FY Corporate Compliance Program Plan Region 10 PIHP FY 2018 Corporate Compliance Program Plan 1 Mission The purpose of the Region 10 Corporate Compliance Program Plan is to provide quality care for all the individuals it serves by acting

More information

Prepared with the Assistance of Jacob Harper, Law Clerk, Morgan Lewis. HHS OIG Exclusion Overview 1

Prepared with the Assistance of Jacob Harper, Law Clerk, Morgan Lewis. HHS OIG Exclusion Overview 1 AHLA Institute on Medicare and Medicaid Payment Issues Exclusions and Administrative Sanctions March 20 & 21, 2013 Howard J. Young Partner, Morgan, Lewis & Bockius, LLP Prepared with the Assistance of

More information

C. Enrollees: A Medicaid beneficiary who is currently enrolled in the MCCMH PIHP.

C. Enrollees: A Medicaid beneficiary who is currently enrolled in the MCCMH PIHP. professionally recognized standards for health care. It also includes beneficiary practices that result in unnecessary cost to the Medicaid program. 42 CFR 455.2 B. CMS: Centers for Medicare & Medicaid

More information

CURRICULUM VITAE. SHARON L. McCARTHY (212)

CURRICULUM VITAE. SHARON L. McCARTHY (212) CURRICULUM VITAE SHARON L. McCARTHY (212) 808-8100 smccarthy@kflaw.com PROFESSIONAL POSITIONS: Partner, Kostelanetz & Fink, LLP New York, New York (October 2006 April 2008; April 2009 Present) Special

More information

Commercial Bribery and the New International Norms

Commercial Bribery and the New International Norms The Catholic University of America From the SelectedWorks of Don R Berthiaume Fall October 8, 2009 Commercial Bribery and the New International Norms Don R Berthiaume Available at: https://works.bepress.com/don_berthiaume/6/

More information

The Anesthesia Company Model: Frequently Asked Questions

The Anesthesia Company Model: Frequently Asked Questions The Anesthesia Company Model: Frequently Asked Questions 1. What is the situation in Florida? Florida-specific Issues For several years, FSA members have been contacting the society with reports of company

More information

Ross O. Silverman. Partner Chicago p Practices. Industries. Recognition. Selected Experience.

Ross O. Silverman. Partner Chicago p Practices. Industries. Recognition. Selected Experience. Ross O. Silverman Partner ross.silverman@kattenlaw.com Chicago p +1.312.902.5240 Practices FOCUS: Litigation Insurance and Health Care Fraud Litigation White Collar, Investigations and Compliance Tax Controversy

More information

A DISCUSSION WITH THE OIG

A DISCUSSION WITH THE OIG 1 A DISCUSSION WITH THE OIG MICHAEL J ARMSTRONG REGIONAL INSPECTOR GENERAL FOR AUDIT SERVICES STEPHEN J CONWAY DIRECTOR, ADVANCED AUDIT TECHNIQUES ROBERT K DECONTI CHIEF, ADMINISTRATIVE & CIVIL REMEDIES

More information

Contents of Presentation:

Contents of Presentation: Office of the Attorney General Medicaid Fraud and Abuse Control Division Michael E. Brooks, Executive Director Medicaid Fraud and Abuse Control Division Office of the Attorney General mike.brooks@ag.ky.gov

More information

Analysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road

Analysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road National Medicare Prescription Drug Congress Analysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road T. Reed Stephens Health Care Practice Group

More information

MEMORANDUM OF UNDERSTANDING

MEMORANDUM OF UNDERSTANDING Activities of the Health and Human Services Commission and the Office of the Attorney General in Detecting and Preventing Fraud, Waste, and Abuse in the State Medicaid Program MEMORANDUM OF UNDERSTANDING

More information

Improving Integrity in Nursing Centers

Improving Integrity in Nursing Centers Improving Integrity in Nursing Centers Susan Edwards Reed Smith LLP AHCA/NCAL s General Counsel Goals of this webinar Introduce you to AHCA/NCAL s Fraud and Abuse Toolkit Provide you with a basic understanding

More information

Coding Partners in Patient Safety

Coding Partners in Patient Safety Coding Partners in Patient Safety Senior Loss Prevention Attorney UF Self Insurance Programs Learning Objectives Understand federal fraud and abuse laws and the importance of coders in avoiding issues.

More information

FALSE CLAIMS ACT ENFORCEMENT: RECENT TRENDS AND STEPS TO ENSURE COMPLIANCE AND AVOID FRAUD ALLEGATIONS

FALSE CLAIMS ACT ENFORCEMENT: RECENT TRENDS AND STEPS TO ENSURE COMPLIANCE AND AVOID FRAUD ALLEGATIONS FALSE CLAIMS ACT ENFORCEMENT: RECENT TRENDS AND STEPS TO ENSURE COMPLIANCE AND AVOID FRAUD ALLEGATIONS The Carolinas Center s 39 th Annual Hospice & Palliative Care Conference Columbia, SC Presenters:

More information

I nsurance brokers and investment banks have at

I nsurance brokers and investment banks have at Securities Regulation & Law Report Reproduced with permission from Securities Regulation & Law Report, 44 SRLR 1030, 05/12/2012. Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

More information

City/State: From: To: City/State: From: To: City/State: From: To:

City/State: From: To: City/State: From: To: City/State: From: To: 2. If you are currently insured on a claims-made policy, are you obtaining Extended Reporting Period (tail) from your current insurance carrier? Yes No N/A (have occurrence coverage now) Note: To prevent

More information

WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER

WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER January 24, 2017 Andrew N. Meyercord Gray Reed & McGraw 1601 Elm Street Suite 4600 Dallas, Texas 75201 214.954.4135 ameyercord@grayreed.com 129 attorneys Full-service,

More information

SIGNIFICANT SETTLEMENTS

SIGNIFICANT SETTLEMENTS Chapter 22 SIGNIFICANT SETTLEMENTS MADELEINE MCDONOUGH, RIKIN MEHTA,* AND JENNIFER STONECIPHER HILL I. Introduction The year 2012 was a record one for settlements involving the pharmaceutical industry.

More information

Federal Administrative Sanctions

Federal Administrative Sanctions FEDERAL AND STATE ADMINISTRATIVE SANCTIONS HCCA COMPLIANCE INSTITUTE April 23, 2007 Chicago, IL Edgar D. Bueno Pillsbury Winthrop Shaw Pittman LLP John W. O Brien Office of Counsel to the Inspector General

More information

Anti-Fraud Policy. The following non-exhaustive list provides a few examples of fraud that this Policy is designed to prevent and detect:

Anti-Fraud Policy. The following non-exhaustive list provides a few examples of fraud that this Policy is designed to prevent and detect: Introduction Anti-Fraud Policy In some instances, Medicaid pays for some or all of the services provided. It is the policy of Helper s Inc. to comply with all applicable federal, state and local laws and

More information

Pharmacy Compliance. Oversight - Many Watchful Eyes. Historical Pharmacy Compliance Programs

Pharmacy Compliance. Oversight - Many Watchful Eyes. Historical Pharmacy Compliance Programs Pharmacy Compliance HCCA Regional Conference San Juan, Puerto Rico April 30, 2015 Daniel Fitzgerald Senior Counsel, Pharmacy Law Department, Walgreen Co. Jose A. Ramos Senior Special Agent, Office of Investigations

More information

Beyond Sunshine: Looking Ahead to Fraud and Abuse Risks Raised by Transparency Reports

Beyond Sunshine: Looking Ahead to Fraud and Abuse Risks Raised by Transparency Reports BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Beyond Sunshine: Looking Ahead to Fraud and Abuse Risks

More information

Coverage Issues Relating To Claims Under The False Claims Act

Coverage Issues Relating To Claims Under The False Claims Act Coverage Issues Relating To Claims Under The False Claims Act May 2, 2017 Stephen A. Wood Chuhak & Tecson, P.C. 30 South Wacker, Ste 2600 Chicago, IL 60606 swood@ Direct Dial: 312-201-3400 Facsimile: 312-444-9027

More information

Board Fiduciary Duty of Care & Individual Liability

Board Fiduciary Duty of Care & Individual Liability Robert N. Rabecs, Esq. Partner 480.824.7916 Bob.Rabecs@huschblackwell.com Board Fiduciary Duty of Care & Individual Liability March 23, 2017 SLC 8184743 Husch Blackwell LLP Agenda Corporate Board Fiduciary

More information

Corporate Compliance Program. Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey -

Corporate Compliance Program. Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey - Corporate Compliance Program Intended Audience: All SEH Associates 2016 Content Expert: Lisa Frey - lisa.frey@stelizabeth.com Developed 2012, reviewed Dec 2015 What is Corporate Compliance? Hospitals,

More information

Recent False Claims Act enforcement trends affecting managed care organizations. Navigating regulatory challenges in a managed care environment

Recent False Claims Act enforcement trends affecting managed care organizations. Navigating regulatory challenges in a managed care environment David Leviss, Partner, O Melveny & Myers LLP Christopher Horan, VP Corporate Compliance Investigations, WellCare Health Plans, Inc. November 2017 Recent False Claims Act enforcement trends affecting managed

More information

FEDERAL DEFICIT REDUCTION ACT POLICY

FEDERAL DEFICIT REDUCTION ACT POLICY A. Introduction. FEDERAL DEFICIT REDUCTION ACT POLICY Partnership for Children of Essex, Inc. (referred to herein as the Organization ) has instituted this Federal Deficit Reduction Act Policy as part

More information

Federal Deficit Reduction Act of 2005, Section 6032 on Fraud, Waste, and Abuse

Federal Deficit Reduction Act of 2005, Section 6032 on Fraud, Waste, and Abuse Policy Number: 4003 Page: 1 of 8 POLICY: It is the policy of Bridgeway Rehabilitation Services, Inc. to obey all federal and state laws and to implement and enforce procedures to detect and prevent fraudulent

More information

HELAINE GREGORY, ESQ.

HELAINE GREGORY, ESQ. HCCA Puerto Rico Regional Annual Conference May 3, 2013 MODERATOR HELAINE GREGORY, ESQ. HCCA CONFERENCE CO-CHAIR PANEL DOROTHY DEANGELIS FTI CONSULTING MAITE MORALES MARTINEZ, ESQ., LL.M. MEDICAL CARD

More information

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016 COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS Judd Katz JD MHA November 2016 Background information Patient Assistance Programs Copay Cards/Assistance Programs Reimbursement Support AGENDA

More information

Self-Disclosure: Why, When, Where and How

Self-Disclosure: Why, When, Where and How American Bar Association Washington Health Law Summit Self-Disclosure: Why, When, Where and How December 8, 2015 Margaret Hutchinson U.S. Attorney s Office for the Eastern District of Pennsylvania Kaitlyn

More information

Charging, Coding and Billing Compliance

Charging, Coding and Billing Compliance GWINNETT HEALTH SYSTEM CORPORATE COMPLIANCE Charging, Coding and Billing Compliance 9510-04-10 Original Date Review Dates Revision Dates 01/2007 05/2009, 09/2012 POLICY Gwinnett Health System, Inc. (GHS),

More information

APPROACHES FOR HOSPITALS CONFRONTING STARK AND ANTI-KICKBACK ISSUES

APPROACHES FOR HOSPITALS CONFRONTING STARK AND ANTI-KICKBACK ISSUES APPROACHES FOR HOSPITALS CONFRONTING STARK AND ANTI-KICKBACK ISSUES CORRECTIVE ACTION, PHYSICIAN NEGOTIATION, AND VOLUNTARY DISCLOSURE; CASE STUDIES Dennis Diaz Partner Davis Wright Tremaine LLP Jim Watson

More information